...
首页> 外文期刊>Cytotechnology >Targeting human telomerase for cancer therapeutics
【24h】

Targeting human telomerase for cancer therapeutics

机译:靶向人类端粒酶用于癌症治疗

获取原文
   

获取外文期刊封面封底 >>

       

摘要

The enzyme telomerase is involved in the replication of telomeres, specialized structures that cap and protect the ends of chromosomes. Its activity is required for maintenance of telomeres and for unlimited lifespan, a hallmark of cancer cells. Telomerase is overexpressed in the vast majority of human cancer cells and therefore represents an attractive target for therapy. Several approaches have been developed to inhibit this enzyme through the targeting of its RNA or catalytic components as well as its DNA substrate, the single-stranded 3′-telomeric overhang. Telomerase inhibitors are chemically diverse and include modified oligonucleotides as well as small diffusable molecules, both natural and synthetic. This review presents an update of recent investigations pertaining to these agents and discusses their biological properties in the context of the initial paradigm that the exposure of cancer cells to these agents should lead to progressive telomere shortening followed by a delayed growth arrest response.
机译:端粒酶参与端粒的复制,端粒是封闭和保护染色体末端的特殊结构。它的活性是维持端粒和无限寿命(癌细胞的标志)所必需的。端粒酶在绝大多数人类癌细胞中过表达,因此代表了一种有吸引力的治疗靶标。已经开发了几种通过靶向其RNA或催化成分以及其DNA底物(单链3'-端粒突出端)来抑制该酶的方法。端粒酶抑制剂在化学上是多种多样的,包括修饰的寡核苷酸以及天然和合成的小的可扩散分子。这篇综述提供了有关这些药物的最新研究的最新进展,并在以下范式的背景下讨论了它们的生物学特性,即癌细胞暴露于这些药物应导致渐进的端粒缩短,随后是延迟的生长停滞反应。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号